Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
evidence of the efficacy of bevacizumab in patients with HHT.Both cases also show that symptoms and transfusion requirements improve with this therapy, without an appreciable change in arteriovenous malformations.Like Oosting et al., we found no difference in the size of our patient's pulmonary arteriovenous malformations on CT before and after bevacizumab.Their experience demonstrates the long-term safety and tolerability of bevacizumab in such patients.Our patient continues to report symptomatic benefit more than a year after completing therapy, and he has required only one intravenous infusion of iron during this time.His hemoglobin levels have remained stable at 14 to 15 g per deciliter.The cost of our patient's regimen (a total of 30 mg per kilogram over four cycles) would be approximately $12,000 today.The costs of continuing the drug in the long term, especially without a Food and Drug Administration-approved indication, would be prohibitive.Our case shows that intermittent dosing allows for long-term, symptomatic improvement and stability of pulmonary arteriovenous malformations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this patient, RDN resulted in a progressive decrease in blood pressure from 161/107 mmHg at baseline to 127/81 mmHg at 12-month follow-up.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“However, RDN-induced reductions in MSNA18 and beneficial effects of RDN on conditions that are not traditionally thought to be driven by the kidney, including heart failure and arrthymia19, cannot be wholly explained by alterations in body fluid homeostasis.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“ablation of the renal nerves was also associated with a substantial decrease in muscle sympathetic nerve activity (MSNA), from 56 bursts per minute before RDN to 19 bursts per minute at 12 months after the procedure.”
From Renal nerves in physiology, pathophysiology and interoception (2025) · cites this paper as [18]
In the citing paper
“The hypothesis that renal afferents mediate some of the BP effects of RDN in humans was sparked by the finding that whole-body noradrenaline spillover and MSNA were decreased in a single patient 1 year after RDN170.”
From Obesity, kidney dysfunction and hypertension: mechanistic links (2019) · cites this paper as [170]
Citations
Cites
Krum, H., Schlaich, M., Whitbourn, R., Sobotka, P. A., Sadowski, J., Bartus, K., Kapelak, B., Walton, A., Sievert, H., Thambar, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60566-3 · Cited by 2,108
Self-citationNeural control of renal function
DiBona, G. F., & Kopp, U. C. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.1.75 · Cited by 1,212
Sympathetic Overactivity in Patients with Chronic Renal Failure
Converse, R. L., Jacobsen, T. N., Toto, R. D., Jost, C. M. T., Cosentino, F., Fouad-Tarazi, F., & Victor, R. G. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212313272704 · Cited by 1,132
Schlaich, M. P., Lambert, E., Kaye, D. M., Krozowski, Z., Campbell, D. J., Lambert, G., Hastings, J., Aggarwal, A., & Esler, M. D. (2004) · Hypertension · doi:10.1161/01.hyp.0000103160.35395.9e · Cited by 514
Self-citationNoradrenaline Release and the Pathophysiology of Primary Human Hypertension
Esler, M., Jennings, G., & Lambert, G. (1989) · American Journal of Hypertension · doi:10.1093/ajh/2.3.140s · Cited by 138
Self-citation
Cited by
Items 401–500 of 763
Bartuś, K., Sadowski, J., Kapelak, B., Litwinowicz, R. A., Zajdel, W., Godlewski, J., Bartuś, M., Zmudka, K. F., Chrapusta, A., Konstanty‐Kalandyk, J., et al. (2014) · Kardiologia Polska · doi:10.5603/kp.a2013.0357 · Cited by 8
Self-citationZhang, Z., Yang, K., Zeng, L., Wang, X., Jiang, F., Tu, S., Liang, Q., & Shen, Z. (2016) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12661 · Cited by 9
Vuignier, Y., Grouzmann, E., Müller, O., Vakilzadeh, N., Faouzi, M., Maillard, M. P., Qanadli, S. D., Burnier, M., & Wuerzner, G. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00042 · Cited by 9
“In contrast, renal norepinephrine spillover was reduced in ten patients studied in the SIMPLICITY-1 trial (1, 29).”
BackgroundMcArdle, Z. M., Filho, R. A. P., Yao, S. T., Lankadeva, Y. R., Singh, R. R., Hood, S. G., Schlaich, M. P., May, C. N., & Booth, L. C. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00228.2018 · Cited by 8
Self-citationTang, X., Shi, L., Cui, X., Yu, Y., Qi, T., Chen, C., & Tang, X. (2017) · Experimental Physiology · doi:10.1113/ep086370 · Cited by 9
Increased sympathetic drive during the onset of hypertension in conscious Cyp1a1-Ren2 rats
Han, S. Y., Gray, E. A., Hughes, G., Brown, C. H., & Schwenke, D. O. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1338-5 · Cited by 8
“Although the recent (re)advent of renal nerve ablation has ensured that hypertension can be effectively “managed,” even in a large cohort of drug-resistant hypertensive patients [49, 53, 54], renal nerve ablation is not successful for all patients [14] and, more importantly, renal nerve ablation (or pharmacological in…”
Lemery, R. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.01.024 · Cited by 8
Effect of renal denervation on long-term outcomes in patients with resistant hypertension
Liang, B., Liang, Y., Li, R., & Gu, N. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01309-3 · Cited by 8
“RDN also reduced whole-body norepinephrine spillover [49], did not significantly change plasma catecholamines [46], and had a mixed influence on aldosterone [45, 47, 48, 50].”
BackgroundKario, K., Alkatiri, A. A., Aoki, J., Ahmad, W. A. W., Chia, Y. C., Cruz, J. N. M., Lee, Y., Lim, S. T., Lu, C., Nguyen, Q. N., et al. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.25333 · Cited by 9
Brain Gαi2-subunit proteins and the prevention of salt sensitive hypertension
Carmichael, C. Y., & Wainford, R. D. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00233 · Cited by 8
“…pathophysiology of salt-sensitive hypertension provides renewed support for the decades of evidence that have documented a role of the renal sympathetic nerves in the pathogenesis of hypertension in multiple animal models (DiBona and Esler, 2010) and in human hypertension (Schlaich et al., 2009).”
BackgroundRenal denervation: time to open Pandora’s box
Gu, Y., Asayama, K., Liu, Y.-P., & Staessen, J. A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13638 · Cited by 8
Orekhov, A. Y., & Karazhanova, L. K. (2022) · Arterial’naya Gipertenziya (Arterial Hypertension) · doi:10.18705/1607-419x-2022-28-4-348-356 · Cited by 7
Does Renal Artery Supply Indicate Treatment Success of Renal Denervation?
Schmid, A., Ditting, T., Sobotka, P. A., Veelken, R. A., Schmieder, R. E., Uder, M., & Ott, C. (2013) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-013-0652-9 · Cited by 7
“Results from assessment of muscle sympathetic nerve activity (MSNA) using microneurography were limited for a long time to a single case report [13].”
MethodSelf-citationRenal Sympathetic Denervation: Hibernation or Resurrection?
Papademetriou, V., Doumas, M. N., & Tsioufis, C. P. (2016) · Cardiology · doi:10.1159/000446909 · Cited by 8
Denegri, A., Naduvathumuriyil, T., Lüscher, T. F., & Sudano, I. (2018) · Journal of Clinical Hypertension · doi:10.1111/jch.13252 · Cited by 8
Sympathetic overactivation predicts body weight loss in patients with heart failure
Joho, S., Ushijima, R., Nakagaito, M., & Kinugawa, K. (2019) · Autonomic Neuroscience · doi:10.1016/j.autneu.2019.102625 · Cited by 9
Bertog, S. C., Sharma, A. K., Mahfoud, F., Pathak, A., Schmieder, R. E., Sievert, K., Papademetriou, V., Weber, M. A., Haratani, N., Lobo, M. D., et al. (2020) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2020.09.003 · Cited by 7
Tuohy, S., Kyvelou, S.-M., Gleeson, P. J., Daniels, F., Ryan, L. A., Lappin, D. W. P., O'Donnell, M. J., & Sharif, F. (2015) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-015-1324-3 · Cited by 7
“Other studies have shown that RSD decreases sympathetic activity in human subjects [11–14].”
BackgroundCatheter-based Arterial Sympathectomy: Hypertension and Beyond
Prince, E. A., Murphy, T. P., & Hampson, C. O. (2012) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2012.06.018 · Cited by 7
Wehrwein, E. A., & Barman, S. M. (2013) · Autonomic Neuroscience · doi:10.1016/j.autneu.2013.07.004 · Cited by 7
“The recent use of a catheter-based radiofrequency renal denervation technique has been successful in reversing the heightened levels of arterial pressure (AP) and muscle sympathetic nerve activity (MSNA) in a cohort of hypertensive patients with end stage renal disease (Schlaich et al, 2009).”
Renal Denervation in the Treatment of Hypertension
Ukena, C., Mahfoud, F., Ewen, S., Cremers, B., Laufs, U., & Böhm, M. (2013) · Current Hypertension Reports · doi:10.1007/s11906-013-0363-2 · Cited by 7
Makowski, K., Gielerak, G. G., Kramarz, E., Wierzchoń, S. T., Kamiński, G., Kowal, J., Krzesiński, P., Żegadło, A., & Skrobowski, A. (2013) · Journal of Human Hypertension · doi:10.1038/jhh.2013.10 · Cited by 9
Renal denervation in patients with resistant hypertension: Six-month results
Dores, H., Almeida, M., Gonçalves, P. D. A., Branco, P. Q., Gaspar, A., Sousa, H., Gomes, Â. C., Andrade, M. J., Carvalho, M. S., Teles, R. C., et al. (2014) · Revista Portuguesa de Cardiologia (English Edition) · doi:10.1016/j.repce.2013.09.016 · Cited by 9
“Chronic activation of the sympathetic nervous system is an important mechanism in resistant HTN, and so a new interventional technique -- renal denervation (RDN) -- has been developed, consisting of endovascular application of radiofrequency energy in the renal arteries to modulate renal sympathetic activity.(10,11) T…”
Eikelis, N., Hering, D., Marušić, P., Walton, A., Lambert, É., Sata, Y., Krum, H., Lambert, G. W., Esler, M., & Schlaich, M. P. (2016) · Journal of Human Hypertension · doi:10.1038/jhh.2016.64 · Cited by 9
Self-citationSham trials: benefits and risks for cardiovascular research and patients
Fudim, M., Ahmed, F. A., Patel, M. R., & Sobotka, P. A. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31120-1 · Cited by 7
Self-citationCentral Sympathetic Inhibition: a Neglected Approach for Treatment of Cardiac Arrhythmias?
Cagnoni, F., Destro, M., Bontempelli, E., Locatelli, G., Hering, D., & Schlaich, M. P. (2016) · Current Hypertension Reports · doi:10.1007/s11906-015-0619-0 · Cited by 7
“Catheter-based renal denervation (RDN) is an interventional therapeutic approach aimed at reducing sympathetic activity and blood pressure in resistant hypertensive patients [84-90] (Figure 1).”
BackgroundSelf-citationSchmidt, M. U., Roessner, F., Berger, M., Tesche, C., Rieber, J., Bauner, K. U., Huber, A. M. A., Rummeny, E. J., Hoffmann, E., & Ebersberger, U. (2019) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000399 · Cited by 8
Bilateral nephrectomy for uncontrolled hypertension in hemodialysis patient: A forgotten option?
Knehtl, M., Bevc, S., Hojs, R., Hlebič, G., & Ekart, R. (2014) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2014.07.484 · Cited by 8
Electric Nerve Stimulation to Monitor the Efficacy of Renal Denervation
Persu, A., Scavée, C., Staessen, J. A., & Blankestijn, P. J. (2013) · Hypertension · doi:10.1161/hypertensionaha.111.00389 · Cited by 7
Le syndrome cardiorénal : diagnostic, physiopathologie et prise en charge
Goursaud, S., & du Cheyron, D. (2014) · Réanimation · doi:10.1007/s13546-014-0897-6 · Cited by 9
“supposé un effet bénéfique de la dénervation rénale sympathique sur le contrôle de l’hypertension artérielle [21], cette hypothèse vient d’être clairement mise à mal par les résultats négatifs récents de l’étude randomisée en simple insu SYM-”
Dénervation rénale endovasculaire par radiofréquence dans l’hypertension artérielle résistante
Steichen, O., Sapoval, M. R., Frank, M., Bobrie, G., Plouin, P., & Azizi, M. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.05.009 · Cited by 9
“[23] Schlaich MP, Sobotka PA, Krum H, Lambert E, Es ler MD.”
BackgroundDrug Resistant Hypertension - No SIMPLE Way Out
Skrzypecki, J., & Ufnal, M. (2015) · Kidney & Blood Pressure Research · doi:10.1159/000368483 · Cited by 6
Zheng, X., Li, X., Lyu, Y., He, Y., Wan, W., Zhu, H., & Jiang, X. (2015) · Experimental Physiology · doi:10.1113/ep085302 · Cited by 6
“study is consistent with previous studies (Schlaich et al. 2009; Schirmer et al. 2015; Thaung et al. 2015).”
ResultMilano, S., Carmosino, M., Gerbino, A., Saponara, I., Lapi, D., Monte, M. D., Bagnoli, P., Svelto, M., & Procino, G. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.695824 · Cited by 6
Catheter-Based Renal Denervation Therapy: Evolution of Evidence and Future Directions
Kandzari, D. E. (2021) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.121.011130 · Cited by 6
Novel and Nonpharmacologic Approaches to Cardio-Protection in Hypertension
Donazzan, L., Mahfoud, F., Linz, D., Ewen, S., Ukena, C., & Böhm, M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0430-3 · Cited by 6
Catheter-based renal denervation for treatment of resistant hypertension
Hatipoglu, E., & Ferro, A. (2013) · JRSM Cardiovascular Disease · doi:10.1177/2048004013486634 · Cited by 6
The Sympathetic Nervous System in Hypertension
Seravalle, G., Mancia, G., & Grassi, G. M. (2018) · Contemporary Endocrinology · doi:10.1007/978-3-319-77048-2_14 · Cited by 7
Chen, H., Ji, M., Zhang, Y., Xu, Y., Qiao, L., Shen, L., & Ge, J. (2019) · Trials · doi:10.1186/s13063-019-3693-9 · Cited by 6
Versaci, F., Sciarretta, S., Scappaticci, M., Pietro, R. D., Calcagno, S., Prete, A. D., Gaspardone, C., & Biondi‐Zoccai, G. (2021) · European Heart Journal Supplements · doi:10.1093/eurheartj/suab117 · Cited by 7
Renal Denervation: Intractable Hypertension and Beyond
Ariyanon, W., Mao, H., Adýbelli, Z., Romano, S., Rodighiero, M., Reimers, B., Vecchia, L. L., & Ronco, C. (2014) · Cardiorenal Medicine · doi:10.1159/000357597 · Cited by 7
Banga, S., Mungee, S., Patel, A. R., Singh, S., & Kizhakekuttu, T. J. (2019) · Cureus · doi:10.7759/cureus.5371 · Cited by 8
Vink, E. E., & Blankestijn, P. J. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.00477 · Cited by 7
Renal Denervation for Hypertension: The Current Landscape and Future Directions
Fulton, B. L., Giri, J. S., Rader, F., Cohen, D. L., & Kobayashi, T. (2024) · Heart International · doi:10.17925/hi.2024.18.1.2 · Cited by 7
Bytyqi, V., Kannenkeril, D., Schmid, A., Striepe, K., Bosch, A., Karg, M. V., Schiffer, M., Uder, M., & Schmieder, R. E. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf184 · Cited by 9
“By reducing sympathetic influence on renal vascular resistance, renin release and sodium reabsorption, RDN targets key factors that contribute to the maintenance and progression of hypertension [12 ].”
Aorticorenal ganglion ablation for blood pressure lowering in canine models
Xu, T., Lou, Y., Li, Q., & Huang, J. (2025) · Hypertension Research · doi:10.1038/s41440-025-02129-8 · Cited by 7
Kanai, T., & Krum, H. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2013.06.002 · Cited by 7
Self-citationRenal Sympathetic Denervation for Treatment of Hypertension
Pimenta, E., & Oparil, S. (2012) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-012-0166-9 · Cited by 6
Secco, G. G., Micari, A., Vadalà, G., Lanteri, S., Parisi, R., Fattori, R., Cremonesi, A., Zeller, T., & Catriota, F. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.167 · Cited by 5
“Renal nerve ablation (RNA) using radiofrequency (RF) catheter-based has been recently proposed for the treatment of severe drug-resistant hypertension [1].”
Diabetes and Metabolic Syndrome
Mahfoud, F., Ewen, S., & Böhm, M. (2014) · Springer eBooks · doi:10.1007/978-1-4471-5223-1_23 · Cited by 5
Sesa‐Ashton, G., Carnagarin, R., Nolde, J. M., Muente, I., Lee, R. C., Macefield, V. G., Dawood, T., Sata, Y., Lambert, É., Lambert, G. W., et al. (2024) · Journal of Hypertension · doi:10.1097/hjh.0000000000003655 · Cited by 7
“This may be a useful tool for integration into clinical assessment of patient suitability and likelihood for a clinically relevant BP lowering response in”
MethodSelf-citationRoditi, G. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22675 · Cited by 5
“However, in the longer term MRI may prove useful for surveillance of these patients as there is potential theoretical risk of late renal artery stenosis while cardiac MRI could be used to measure regression of left ventricular mass as a marker of sustained therapeutic success (80).”
BackgroundQuinn, M. (2011) · Journal of the Royal Society of Medicine · doi:10.1258/jrsm.2011.110014 · Cited by 7
Technical and safety aspects of renal denervation
Čurila, K., Rosa, J., Toušek, P., Widimsky, J., Jr., & Widimský, P. (2014) · Cor et Vasa · doi:10.1016/j.crvasa.2014.02.004 · Cited by 5
Tsioufis, C. P., Dimitriadis, K. S., Tsiachris, D., Thomopoulos, C., Kasiakogias, A., Kordalis, A., Kefala, A., Kallikazaros, I. E., & Stefanadis, C. (2012) · PubMed · Cited by 8
Integrative Blood Pressure Response to Upright Tilt Post Renal Denervation
Howden, E. J., East, C. A., Lawley, J. S., Stickford, A. S. L., Verhees, M. J. M., Fu, Q., & Levine, B. D. (2017) · American Journal of Hypertension · doi:10.1093/ajh/hpx018 · Cited by 5
Wallbach, M., Koziolek, M. J., & Wachter, R. (2018) · Der Internist · doi:10.1007/s00108-018-0488-0 · Cited by 7
Garg, J., Shah, S., Shah, K. B., Turagam, M. K., Natale, A., & Lakkireddy, D. (2021) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.14230 · Cited by 5
Nazari, S., Haghani, M., & Moosavi, S. M. S. (2021) · Experimental Physiology · doi:10.1113/ep089545 · Cited by 5
“There is substantial evidence that obesity contributes some 65– 75% of the risk of developing essential hypertension (DeMarco et al., 2014; Hall et al., 2010, 2014; Seravalle & Grassi, 2017).”
BackgroundFilho, R. A. P., Nishi, E. E., Crajoinas, R. O., Milanez, M. I. O., Girardi, A. C. C., Campos, R. R., & Bergamaschi, C. T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010349 · Cited by 8
Catheter-based renal artery denervation: facts and expectations
Verdecchia, P., Cavallini, C., Sclafani, R., Santucci, A., Notaristefano, F., Zingarini, G., Colombo, G., & Angeli, F. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.07.041 · Cited by 6
Renal Sympathetic Denervation for Treatment of Resistant Hypertension: Egyptian Experience
Hamza, M. T., & Khamis, H. (2014) · Journal of Interventional Cardiology · doi:10.1111/joic.12135 · Cited by 5
Li, H., Yu, H., Zeng, C., Fang, Y., He, D., Zhang, X., Wen, C., & Yang, C. (2014) · Clinical and Experimental Hypertension · doi:10.3109/10641963.2014.933970 · Cited by 5
“Additional evidence comes from a case report showing that this procedure caused a halving of renin activity (11).”
BackgroundA Profile of Renal Function in Northern Cameroonians with Essential Hypertension
Tamanji, M. T., Ngwakum, D. A., & Mbouemboue, O. P. (2017) · Cardiorenal Medicine · doi:10.1159/000455680 · Cited by 5
Renal denervation: dark past, bright future?
Heradien, M., Mahfoud, F., Hettrick, D., & Brink, P. A. (2019) · Cardiovascular journal of South Africa/Cardiovascular journal of Southern Africa · doi:10.5830/cvja-2019-045 · Cited by 8
“RD has not been tested in patients with secondary HT, but it could theoretically reduce BP in patients with inoperable paragangliomas, since RD reduces circulating catecholamine levels.(46) Finally, although RD probably reduces BP, if correctly performed, patients should continue to take their BP medication.”
BackgroundDevice-Based Approaches to Modulate the Autonomic Nervous System and Cardiac Electrophysiology
Hucker, W. J., Singh, J. P., Parks, K. A., & Armoundas, A. A. (2011) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2011.3.1.30 · Cited by 5
Scholz, E., Raake, P. W. J., Thomas, D., Vogel, B., Katus, H. A., & Blessing, E. (2014) · Clinical Research in Cardiology · doi:10.1007/s00392-014-0769-0 · Cited by 5
“From an experimental point of view, RDN has been shown to reduce sympathetic nerve activity, norepinephrine spillover and ischemia-induced ventricular arrhythmias [3, 4].”
BackgroundRenal denervation for resistant hypertension—the Symplicity HTN-1 study – Authors' reply
Krum, H., Sobotka, P. A., Schlaich, M. P., Böhm, M., & Esler, M. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60913-2 · Cited by 5
Self-citationStenting for Renal-Artery Stenosis
Murphy, T. P., Dworkin, L. D., & Cooper, C. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmc1402687 · Cited by 5
White, C. J., & Reilly, J. P. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.04.034 · Cited by 5
“SEE PAGE 1292 E arly trials demonstrated that renal artery denervation (RDN), delivered with a catheter in the renal artery, reduced blood pressure by reducing sympathetic tone in patients with hypertension, as measured by renal norepinephrine spillover and muscular sympathetic nerve activity (1).”
BackgroundSympathetic drive stimulating diastolic dysfunction?
Ahmad, S. S., & Gerson, M. C. (2017) · Journal of Nuclear Cardiology · doi:10.1007/s12350-017-0809-z · Cited by 5
Targeting renal nerves for arterial hypertension – The path to renal denervation
Sesa‐Ashton, G., Herat, L. Y., & Schlaich, M. P. (2025) · Autonomic Neuroscience · doi:10.1016/j.autneu.2025.103313 · Cited by 6
Self-citationGrassi, G. M., Seravalle, G., Brambilla, G., Corso, R., Stella, A., & Mancia, G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.10.020 · Cited by 4
“In a seventy-two year old man with a medical history of resistant hypertension in which it was not possible to perform bilateral renal denervation due to technical problems (see below), we measured clinic (sphygmomanometer), finger beat-to-beat (Finapres, Ohmeda, CA, USA) and ambulatory (SpaceLab 90207, Redmond, WA, U…”
BackgroundMethodHagiwara, S., Jha, J. C., & Cooper, M. E. (2013) · Diabetology International · doi:10.1007/s13340-013-0148-5 · Cited by 4
“Recently, successful targeting of the sympathetic nervous system as a hypotensive strategy by bilateral renal denervation has been examined [71, 72].”
BackgroundBosch, A., Schmid, A., Ott, C., Kannenkeril, D., Karg, M. V., Ditting, T., Veelken, R. A., Uder, M., & Schmieder, R. E. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz155 · Cited by 5
Dell’Oro, R., Quarti‐Trevano, F., Seravalle, G., Cuspidi, C., & Grassi, G. M. (2023) · Clinical Autonomic Research · doi:10.1007/s10286-023-00927-z · Cited by 4
“Multi-unit recordings of MSNA or SSNA were obtained through a tungsten microelectrode inserted into a peroneal nerve posterior to the fibular head, as reported previously [1, 7, 11, 15].”
Radiofrequency ablation of renal sympathetic nerve: Numerical simulation and ex vivo experiments
Dong, T., Nan, Q., Tian, Z., & Cheng, Y. (2018) · Advances in Mechanical Engineering · doi:10.1177/1687814018781284 · Cited by 4
“By avoiding excessive secretion of norepinephrine, RH is able to be cured with less adverse reactions and patients will rely less on high blood pressure drugs.(16) Krum et al.”
BackgroundGroussin, P., Decaudin, D., Dezecot, M., Marc, T., Béhar, N., Pavin, D., Leclercq, C., Mabo, P., Bénali, K., & Martins, R. P. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.05.001 · Cited by 4
Renal sympathetic denervation for treatment of resistant hypertension – Indigenous technique
Manakshe, G. V., Chakravarthi., R., Hussaini, S., Menon, R. V., Kumar, A., Kiran, V. R., Sundar, G., & Narasimhan, C. (2013) · Indian Heart Journal · doi:10.1016/j.ihj.2013.04.030 · Cited by 4
Where and when Device Therapy May Be Useful in the Management of Drug-Resistant Hypertension
Aronow, H. D., Li, J., & Parikh, S. A. (2014) · Current Cardiology Reports · doi:10.1007/s11886-014-0546-8 · Cited by 4
Koppelstaetter, C., Kerschbaum, J., Lenzhofer, M., Glodny, B., Esterhammer, R., Frick, M., Alber, H. F., & Mayer, G. J. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12456 · Cited by 4
“In 2009, the first-in-man data of 45 successfully treated patients with therapy-refractory hypertension and RDN were presented.(5) In 2010, a randomized controlled trial ascertaining these results in a randomly assigned cohort of 106 patients.”
BackgroundKanai, T., & Krum, H. (2013) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2013.06.001 · Cited by 5
Self-citationCatheter-based renal sympathetic denervation: limitations to and gaps in the evidence
Hiremath, S. S., Froeschl, M. P. V., & Ruzicka, M. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000076 · Cited by 5
“Although there was a considerable decrease in whole body and renal norepinephrine spillover 30 days post-procedure, there was a noticeable difference in response in the right kidney, showing a decrease of 75%, as compared with the left kidney, with a decrease of 48% [19].”
BackgroundInfluentialRenal Denervation: A Novel Therapy at the Crossroads of Imaging, Intervention, and Innovation
Moriarty, J. M., Tung, R. H., Bradfield, J. S., McWilliams, J. P., Lee, E. W., & Kuo, M. (2015) · SLAS TECHNOLOGY · doi:10.1177/2211068215605838 · Cited by 4
“Early human clinical evaluation also mechanistically correlated denervation with reduced norepinephrine spillover, decreased renin activity, and increased renal plasma flow.(28) The first human study of catheter-based renal denervation for RH was published as a proof-of-principle cohort study (Symplicity HTN-1) by Kru…”
BackgroundTiroch, K. A., Sause, A., Szymanski, J., Nover, I., Leischik, R., Mann, J. F. E., Vorpahl, M., & Seyfarth, M. (2015) · EuroIntervention · doi:10.4244/eijv11i7a167 · Cited by 5
Ziakas, A., Petroglou, D., Moralidis, E., Tsioufis, K. P., Doumas, M., Argiriadou, E., Savopoulos, C. G., Hadjimiltiades, S., Stiliadis, I., Κouparanis, A., et al. (2016) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401610010163 · Cited by 4
“Hypertensive patients are known to have an augmented renal norepinephrine spillover, mediated by increased sympathetic innervation of the kidneys [2].”
Prochnau, D., & Hoyme, M. (2018) · Journal of Electrocardiology · doi:10.1016/j.jelectrocard.2018.01.004 · Cited by 4
Renal denervation: the hope for patients with refractory hypertension?
Widimský, P., Osmancik, P. P., & Widimsky, J., Jr. (2011) · Cor et Vasa · doi:10.33678/cor.2011.130 · Cited by 4
Filho, R. A. P., Colombari, D. S. A., Paula, P. M. D., Colombari, E., Andrade, C. A. F., Junior, L. A. D. L., & Menani, J. V. (2023) · Autonomic Neuroscience · doi:10.1016/j.autneu.2023.103107 · Cited by 4
Renal sympathetic denervation in the treatment of resistant hypertension.
Sánchez-Álvarez, C., González-Vélez, M., Stilp, E., Ward, C., & Mena‐Hurtado, C. (2014) · PubMed Central · Cited by 11
Hanssen, T. A., Subbotina, A., Miroslawska, A., Solbu, M. D., & Steigen, T. K. (2022) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2022.2084562 · Cited by 5
Ding, X., Xu, X., Yan, Y., Song, X., Liu, S., Wang, G., Su, D., Jing, Q., & Yong-wen, Q. I. N. (2014) · Herz · doi:10.1007/s00059-014-4110-5 · Cited by 4
Beyond Conventional Considerations: Newer Devices Used in Blood Pressure Measurement and Management
Townsend, R. R., & Sica, D. A. (2011) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.11.002 · Cited by 4
Renal Sympathetic Denervation for the Treatment of Systemic Hypertension
Burke, G. M., Sica, D. A., & Frishman, W. H. (2012) · Cardiology in Review · doi:10.1097/crd.0b013e3182651f91 · Cited by 4
Renal Denervation to Modify Hypertension and the Heart Failure State
Zhong, M., Kim, L. K., Swaminathan, R. V., & Feldman, D. N. (2017) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2017.03.013 · Cited by 4
Renal Nerves and CKD: Is Renal Denervation the Answer?
Humphreys, M. H. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012050513 · Cited by 5
Is There a Role for Renal Sympathetic Denervation in the Future Treatment of Resistant hypertension?
Mahfoud, F., Lenski, M., & Böhm, M. (2011) · Future Cardiology · doi:10.2217/fca.11.49 · Cited by 4
Renal nerve ablation: Emerging role in therapeutics
Oparil, S., Narkiewicz, K., Kjeldsen, S. E., & Hedner, T. (2011) · Blood Pressure · doi:10.3109/08037051.2011.613296 · Cited by 4
May, C. N., & Evans, R. G. (2009) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2009.05341.x · Cited by 4
“The central role of the SNS, as a major causative factor in hypertension, has been highlighted by the recent finding that renal denervation causes a large and sustained decrease in blood pressure in patients with drug-resistant hypertension.(2,3) Interestingly, the fall in pressure caused by renal denervation was acco…”
BackgroundSeptember 10-14 Munich, Germany CIRSE 2011
Gazzera, C., Piccinini, S., Gallesio, C., Veltri, A., & GANDINI, G. (2011) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-011-0216-9 · Cited by 4
Metadata
- Authors
- Schlaich, M. P., Sobotka, P. A., Krum, H., Lambert, E., & Esler, M. D.
- Affiliations
- Baker Heart and Diabetes Institute (AU)
- University of Oklahoma Health Sciences Center (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-08-27
- Volume
- 361
- Issue
- 9
- Pages
- 932-934
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1994487234
- Cited by
- 772
- References
- 5
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 19 · 2023: 25 · 2022: 22 · 2021: 19 · 2020: 19 · 2019: 27 · 2018: 31 · 2017: 42 · 2016: 42 · 2015: 52 · 2014: 115 · 2013: 136 · 2012: 95
- FWCI
- 42.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- uncontrolled hypertension, bevacizumab, hereditary hemorrhagic telangiectasia, pulmonary arteriovenous malformation, intermittent dosing, long-term drug safety, iron requirements
- MeSH terms
- Humans, Hypertension, Kidney, Male, Middle Aged, Norepinephrine, Renal Artery, Sympathectomy, Catheter Ablation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.